# US 2008/0188426 A1 · Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0188426 A1
- Document ID: US20080188426A1
- Status: Published application
- Kind: A1
- Application number: 12/032,411
- Filed: 2008-02-15
- Published: 2008-08-07
- Earliest claimed: 2004-03-04
- Assignees: Kissei Pharmaceutical Co., Ltd.
- Inventors: Nobuhiko FUSHIMI; Hirotaka Teranishi; Kazuo Shimizu; Shigeru Yonekubo; Fumiaki Ito; Masayuki ISAJI
- Web page: https://patentgrep.com/patent/US20080188426A1

## CPC

- A61K 31/7056: containing five-membered rings with nitrogen as a ring hetero atom
- A61K 31/706: containing six-membered rings with nitrogen as a ring hetero atom
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/10: Antioedematous agents; Diuretics
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 13/12: of the kidneys
- A61P 19/06: Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A61P 25/02: for peripheral neuropathies
- A61P 27/02: Ophthalmic agents
- A61P 27/12: for cataracts
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07H 17/02: Heterocyclic radicals containing only nitrogen as ring hetero atoms
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)

## Abstract

The present invention provides nitrogen-containing fused-ring derivatives represented by the following general formula, or pharmaceutically acceptable salts thereof, or prodrugs thereof, which exhibit an excellent inhibitory activity in human SGLT and are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, postprandial hyperglycemia, impaired glucose tolerance, diabetic complications or obesity, in the formula R1 represent H, an optionally substituted alkyl group, an alkenyl group, etc.; R2 represent H, a halogen atom or an alkyl group; R3 and R4 represent H, OH, a halogen atom, an optionally substituted alkyl group, etc.; Y represents CH or N; Q represents alkylene, alkenylene, etc.; ring A represents an aryl group or a heteroaryl group; G represents a group represented by the following general formula (G-1) or (G-2) (in which E1 represents H, F or OH; and E2 represents H, F, a methyl group, etc.), and pharmaceutical compositions comprising the same, and pharmaceutical uses thereof.

## Claims

### Claim at position 1

-18. (canceled)

### Claim 19

A method for the inhibition of postprandial hyperglycemia, which comprises administering an effective amount of a nitrogen-containing fused-ring derivative represented by the following general formula (I):
wherein
R1 represents a hydrogen atom, a C1-6 alkyl group, a halo(C1-6 alkyl) group, a hydroxy(C1-6 alkyl) group, a dihydroxy(C1-6 alkyl) group, a C1-6 alkoxy(C1-6 alkyl) group, a C2-7 alkoxycarbonyl(C1-6 alkyl) group, a carboxy(C1-6 alkyl) group, a C2-6 alkenyl group, -J-N(R5)-Z1, -J-CON(R5)-Z1, or any of the following substituents (a) to (d) which may have any 1 to 3 substituents selected from the later identified substituent group α on the ring;
(a) a C3-7 cycloalkyl group, (b) a C3-7 cycloalkyl(C1-6 alkyl) group, (c) a C6-10 aryl group or (d) a C6-10 aryl(C1-6 alkyl) group,
R2 represents a hydrogen atom, a halogen atom or a C1-6 alkyl group;
R3 and R4 independently represent a hydrogen atom, a hydroxy group, a halogen atom, a C1-6 alkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, a C1-6 alkoxy group, a C2-6 alkenyloxy group, a C1-6 alkylthio group, a C2-6 alkenylthio group, a halo(C1-6 alkyl) group, a halo(C1-6 alkoxy) group, a halo(C1-6 alkylthio) group, a hydroxy(C1-6 alkyl group, a hydroxy(C2-6 alkenyl) group, a hydroxy(C1-6 alkoxy) group, a hydroxy(C1-6 alkylthio) group, a carboxy group, a carboxy(C1-6 alkyl) group, a carboxy(C2-6 alkenyl) group, a carboxy(C1-6 alkoxy) group, a carboxy(C1-6 alkylthio) group, a C2-7 alkoxycarbonyl group, a C2-7 alkoxycarbonyl(C1-6 alkyl) group, a C2-7 alkoxycarbonyl(C2-6 alkenyl) group, a C2-7 alkoxycarbonyl(C1-6 alkoxy) group, a C2-7 alkoxycarbonyl(C1-6 alkylthio) group, a C1-6 alkylsulfinyl group, a C1-6 alkylsulfonyl group, —U—V—W—N(R6)-Z2, or any of the following substituents (i) to (xxviii) which may have any 1 to 3 substituents selected from the later identified substituent group α on the ring;
(i) a C6-10 aryl group, (ii) C6-10 aryl-O—, (iii) C6-10 aryl-S—, (iv) a C6-10 aryl(C1-6 alkyl) group, (v) a C1-6 aryl(C1-6 alkoxy) group, (vi) a C6-10 aryl(C1-6 alkylthio) group, (vii) a heteroaryl group, (viii) heteroaryl-O—, (ix) heteroaryl-S—, (x) a heteroaryl(C1-6 alkyl) group, (xi) a heteroaryl(C1-6 alkoxy) group, (xii) a heteroaryl(C1-6 alkylthio) group, (xiii) a C3-7 cycloalkyl group, (xiv) C3-7 cycloalkl-O—, (xv) C3-7 cyloalkyl-S—, (xvi) a C3-7 cycloalkyl(C1-6 alkyl) group, (xvii) a C3-7 cycloalkyl(C1-6 alkoxy) group, (xviii) a C3-7 cycloalkyl(C1-6 alkylthio) group, (xix) a heterocycloalkyl group, (xx) heterocycloalkyl-O—, (xxi) heterocycloalkyl-S—, (xxii) a heterocycloalkyl(C1-6 alkyl) group, (xxiii) a heterocycloalkyl(C1-6 alkoxy) group, (xxiv) a heterocycloalkyl(C1-6 alkylthio) group, (xxv) an aromatic cyclic amino group, (xxvi) an aromatic cyclic amino(C1-6 alkyl) group, (xxvii) an aromatic cyclic amino(C1-6 alkoxy) group, or (xxviii) an aromatic cyclic amino(C1-6 alkylthio) group,
J represents a C1-6 alkylene group which may have a hydroxy group, or a C2-6 alkenylene group;
U represents —O—, —S— or a single bond and with the proviso that at least one of V and W is not a single bond when U is —O— or —S—;
V represents a C1-6 alkylene group which may have a hydroxy group, a C2-6 alkenylene group, or a single bond;
W represents —CO—, —SO_—, —C(═NH)— or a single bond;
Z1 and Z2 independently represent a hydrogen atom, a C2-7 alkoxycarbonyl group, a C6-10 aryl(C2-7 alkoxycarbonyl) group, a formyl group, —RA, —CORB, —SO2RB, —CON(RC)RD, —CSN(RCC)RD, —SO2NHRA or —C(═NRE)N(RF)RG;
R5, R6, RA, RC and RD independently represent a hydrogen atom, a C1-6 alkyl group which may have any 1 to 5 substituents selected from the later identified substituent group, or any of the following substituents (xxix) to (xxxii) which may have any 1 to 3 substituents selected from the later identified substituent group α;
(xxix) a C6-10 aryl group, (xxx) a heteroaryl group, (xxxi) a C3-7 cycloalkyl group, or (xxxii) a heterocycloalkyl group,
or both of Z1 and R5 or both of Z2 and R6 bind together with the neighboring nitrogen atom to form an aliphatic cyclic amino group which may have any 1 to 3 substituents selected from the later identified substituent group α;
or RC and RD bind together with the neighboring nitrogen atom to form an aliphatic cyclic amino group which may have any 1 to 3 substituents selected from the later identified substituent group α;
RB represents a C2-7 alkoxycarbonyl group, a C1-6 alkylsulfonylamino group, a C6-10 arylsulfonylamino group, a C1-6 alkyl group which may have any 1 to 5 substituents selected from the later identified substituent group β or any of the following substituents (xxxiii) to (xxxvi) which may have any 1 to 3 substituents selected from the later identified substituent group α;
(xxxiii) a C6-10 aryl group, (xxxiv) a heteroaryl group, (xxxv) a C3-7 cycloalkyl group, or (xxxvi) a heterocycloalkyl group,
RE, RF and RG independently represent a hydrogen atom, a cyano group, a carbamoyl group, a C2-7 acyl group, a C2-7 alkoxycarbonyl group, a C6-10 aryl(C2-7 alkoxycarbonyl) group, a nitro group, a C1-6 alkylsulfonyl group, a sulfamoyl group, a carbamimidoyl group, or a C1-6 alkyl group which may have any 1 to 5 substituents selected from the later identified substituent group β;
or RE and RF bind together to form an ethylene group;
or RF and RG bind together with the neighboring nitrogen atom to form an aliphatic cyclic amino group which may have a substituent selected from the later identified substituent group α;
Y represents CH or N;
Q represents —C1-6 alkylene-, —C2-6 alkenylene-, —C2-6 (alkynylene-, —C1-6 alkylene-O—, —C1-6 alkylene-S—, —O—C1-6 alkylene-, —S—C1-6 alkylene-, —C1-6 alkylene-O—C1-6 alkylene-, —C1-6 alkylene-S—C1-6 alkylene-, —CON(R7)—, —N(R7)CO—, —C1-6 alkylene-CON(R7)— or —CON(R7)—C1-6 alkylene-;
R7 represents a hydrogen atom or a C1-6 alkyl group;
ring A represents a C6-10 aryl group or a heteroaryl group;
G represents a group represented by a formula:
or a formula:
E1 represents a hydrogen atom, a fluorine atom or a hydroxy group;
E2 represents a hydrogen atom, a fluorine atom, a methyl group or a hydroxymethyl group;
substituent group α:
a halogen atom, a hydroxy group, an amino group, a C1-6 alkyl soup, a C1-6 alkoxy group, a halo(C1-6 alkyl) group, a halo(C1-6 alkoxy) group, a hydroxy(C1-6 alkyl) group, a C2-7 alkoxycarbonyl(C1-6 alkyl) group, a hydroxy(C1-6 alkoxy) group, an amino(C1-6 alkyl) group, an amino(C1-6 alkoxy) group, a mono or di(C1-6 alkyl)amino group, a mono or di[hydroxy(C1-6 alkyl)]amino group, a C1-6 alkylsulfonyl group, a C1-6 alkylsulfonylamino group, a C1-6 alkylsulfonylamino(C1-6 alkyl) group, a carboxy group, a C2-7 alkoxycarbonyl group, a sulfamoyl group and —CON(RH)RI
substituent group β:
a halogen atom, a hydroxy group, an amino group, a C1-6 alkoxy group, a C1-6 alkylthio group, a halo(C1-6 alkoxy) group, a halo(C1-6 alkylthio) group, a hydroxy(C1-6 alkoxy) group, a hydroxy(C1-6 alkylthio) group, an amino(C1-6 alkoxy) group, an amino(C1-6 alkylthio) group, a mono or di(C1-6 alkyl)amino group, a mono or di[hydroxy(C1-6 alkyl)]amino group, an ureido group, a sulfamide group, a mono or di(C1-6 alkyl)ureido group, a mono or di[hydroxy(C1-6 alkyl)]ureido group, a mono or di(C1-6 alkyl)sulfamide group, a mono or di[hydroxy(C1-6 alkyl)]-sulfamide group, a C2-7 acylamino group, an amino(C2-7 acylamino) group, a C1-6 alkylsulfonyl group, a C1-6 alkylsulfonylamino group, a carbamoyl(C1-6 alkylsulfonylamino) group, a carboxy group, a C2-7 alkoxycarbonyl group, —CON(RH)RI, and any of the following substituents (xxxvii) to (xxxxviii) which may have any 1 to 3 substituents selected from the above substituent group α on the ring;
(xxxvii) a C6-10 aryl group, (xxxviii) C6-10 aryl-O—, (xxxix) a C6-10 aryl(C1-6 alkoxy) group, (xxxx) a C6-10 aryl(C1-6 alkylthio) group, (xxxxi) a heteroaryl group, (xxxxii) heteroaryl-O—, (xxxxiii) a C3-7 cycloalkyl group, (xxxxiv) C3-7 cycloalkyl-O—, (xxxxv) a heterocycloalkyl group, (xxxxvi) heterocycloalkyl-O—, (xxxxvii) an aliphatic cyclic amino group or (xxxxviii) an aromatic cyclic amino group
RH and RI independently represent a hydrogen atom or a C1-6 alkyl group which may have any 1 to 3 substituents selected from the later identified substituent group γ;
or both of RH and RI bind together with the neighboring nitrogen atom to form an aliphatic cyclic amino group which may have any 1 to 3 substituents selected from the later identified substituent group δ;
substituent group γ:
a halogen atom, a hydroxy group, an amino group, a C1-6 alkoxy group, a halo(C1-6 alkoxy) group, a hydroxy(C1-6 alkoxy) group, an amino(C1-6 alkoxy) group, a mono or di(C1-6 alkyl)amino group, a mono or di[hydroxy(C1-6 alkyl)]amino group, an ureido group, a sulfamide group, a mono or di(C1-6 alkyl)ureido group, a mono or di[hydroxy(C1-6 alkyl)]ureido group, a mono or di(C1-6 alkyl)sulfamide group, a mono or di[hydroxy(C1-6 alkyl)]sulfamide group, a C2-7 acylamino group, an amino(C2-7 acylamino) group, a C1-6 alkylsulfonyl group, a C1-6 alkylsulfonylamino group, a carbamoyl(C1-6 alkylsulfonylamino) group, a carboxy group, a C2-7 alkoxycarbonyl group and —CON(RJ)RK
substituent group δ;
a halogen atom, a hydroxy group, an amino group, a C1-6 alkyl group, a C1-6 alkoxy group, a halo(C1-6 alkyl) group, a halo(C1-6 alkoxy) group, a hydroxy(C1-6 alkyl) group, a C2-7 alkoxycarbonyl(C1-6 alkyl) group, a hydroxy(C1-6 alkoxy) group, an amino(C1-6 alkyl) group, an amino(C1-6 alkoxy) group, a mono or di(C1-6 alkyl)amino group, a mono or di[hydroxy(C1-6 alkyl)]amino group, a C1-6 alkylsulfonyl group, a C1-6 alkylsulfonylamino group, a C1-6 alkylsulfonylamino(C1-6 alkyl) group, a carboxy group, a C2-7 alkoxycarbonyl group, a sulfamoyl group and —CON(RJ)RK
RJ and RK independently represent a hydrogen atom or a C1-6 alkyl group which may have any 1 to 3 substituents selected from a hydroxy group, an amino group, a mono or di(C1-6 alkyl)amino group, a C2-7 alkoxycarbonyl group and a carbamoyl group;
or both of RI and RK bind together with the neighboring nitrogen atom to form an aliphatic cyclic amino group which may have any 1 to 3 substituents selected from a hydroxy group, an amino group, a mono or di(C1-6 alkyl)amino group, a C1-6 alkyl group, a hydroxy(C1-6 alkyl) group, a C2-7 alkoxycarbonyl group, a C2-7 alkoxycarbonyl(C1-6 alkyl) group and a carbamoyl group,
or a pharmaceutically acceptable salt thereof.

### Claim 20

A method for the treatment of a disease associated with hyperglycemia, which comprises administering an effective amount of a nitrogen-containing fused-ring derivative represented by the following general formula (I):
wherein
R1 represents a hydrogen atom, a C1-6 alkyl group, a halo(C1-6 alkyl) group, a hydroxy(C1-6 alkyl) group, a dihydroxy(C1-6 alkyl) group, a C1-6 alkoxy(C1-6 alkyl) group, a C2-7 alkoxycarbonyl(C1-6 alkyl) group, a carboxy(C1-6 alkyl) group, a C2-6 alkenyl group, -J-N(R5)-Z1, -J-CON(R5)-Z1, or any of the following substituents (a) to (d) which may have any 1 to 3 substituents selected from the later identified substituent group α on the ring;
(a) a C3-7 cycloalkyl group, (b) a C3-7 cycloalkyl(C1-6 alkyl) group, (c) a C6-10 aryl group or (d) C6-10 aryl(C1-6 alkyl) group,
R2 represents a hydrogen atom, a halogen atom or a C1-6 alkyl group;
R3 and R4 independently represent a hydrogen atom, a hydroxy group, a halogen atom, a C1-6 alkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, a C1-6 alkoxy group, a C2-6 alkenyloxy group, a C1-6 alkylthio group, a C2-6 alkenylthio group, a halo(C1-6 alkyl) group, a halo(C1-6 alkoxy) group, a halo(C1-6 alkylthio) group, a hydroxy(C1-6 alkyl) group, a hydroxy(C2-6 alkenyl) group, a hydroxy(C1-6 alkoxy) group, a hydroxy(C1-6 alkylthio) group, a carboxy group, a carboxy(C1-6 alkyl) group, a carboxy(C2-6 alkenyl) group, a carboxy(C1-6 alkoxy) group, a carboxy(C1-6 alkylthio) group, a C2-7 alkoxycarbonyl group, a C2-7 alkoxycarbonyl(C1-6 alkyl) group, a C2-7 alkoxycarbonyl(C2-6 alkenyl) group, a C2-7 alkoxycarbonyl(C1-6 alkoxy) group, a C2-7 alkoxycarbonyl(C1-6 alkylthio) group, a C1-6 alkylsulfinyl group, a C1-6 alkylsulfonyl group, —U—V—W—N(R6)-Z2, or any of the following substituents (i) to (xxviii) which may have any 1 to 3 substituents selected from the later identified substituent group α on the ring;
(i) a C6-10 aryl group (ii) C6-10 aryl-O—, (iii) C6-10 aryl-S—, (iv) a C6-10 aryl(C1-6 alkyl) group, (v) a C6-10 aryl(C1-6 alkoxy) group (vi) a C6-10 aryl(C1-6 alkylthio) group, (vii) a heteroaryl group, (viii) heteroaryl-O—, (ix) heteroaryl-S—, (x) a heteroaryl(C1-6 alkyl) group, (xi) a heteroaryl(C1-6 alkoxy) group, (xii) a heteroaryl(C1-6 alkylthio) group, (xiii) a C3-7 cycloalkyl group, (xiv) C3-7 cycloalkyl-O—, (xv) C3-7 cycloalkyl-S—, (xvi) a C3-7 cycloalkyl(C1-6 alkyl group, (xvii) a C3-7 cycloalkyl(C1-6 alkoxy) group, (xviii) a C3-7 cycloalkyl(C1-6 alkylthio) group (xix) a heterocycloalkyl group, (xx) heterocycloalkyl-O—, (xxi) heterocycloalkyl-S—, (xxii) a heterocycloalkyl(C1-6 alkyl) group, (xxiii) a heterocycloalkyl(C1-6 alkoxy) group, (xxiv) a heterocycloalkyl(C1-6 alkylthio) group, (xxv) an aromatic cyclic amino group, (xxvi) an aromatic cyclic amino(C1-6 alkyl) group, (xxvii) an aromatic cyclic amino(C1-6 alkoxy) group, or (xxviii) an aromatic cyclic amino(C1-6 alkylthio) group
J represents a C1-6 alkylene group which may have a hydroxy group, or a C2-6 alkenylene group;
U represents —O—, —S— or a single bond and with the proviso that at least one of V and W is not a single bond when U is —O— or —S—;
V represents a C1-6 alkylene group which may have a hydroxy group, a C2-6 alkenylene group or a single bond;
W represents —CO—, —SO2—, —C(═NH)— or a single bond;
Z1 and Z2 independently represent a hydrogen atom, a C2-7 alkoxycarbonyl group, a C6-10 aryl(C2-7 alkoxycarbonyl) group, a formyl group, —RA, —CORB, —SO2RB, —CON(RC)RD, —CSN(RC)RD, —SO2NHRA or —C(═NRE)N(RF)RG;
R5, R6, RA, RC and RD independently represent a hydrogen atom, a C1-6 alkyl group which may have any 1 to 5 substituents selected from the later identified substituent group β or any of the following substituents (xxix) to (xxxii) which may have any 1 to 3 substituents selected from the later identified substituent group α;
(xxix) a C6-10 aryl group, (xxx) a heteroaryl group, (xxxi) a C3-7 cycloalkyl group or (xxxii) a heterocycloalkyl group,
or both of Z1 and R5 or both of Z2 and R6 bind together with the neighboring nitrogen atom to form an aliphatic cyclic amino group which may have any 1 to 3 substituents selected from the later identified substituent group α;
or RC and RD bind together with the neighboring nitrogen atom to form an aliphatic cyclic amino group which may have any 1 to 3 substituents selected from the later identified substituent group α;
RB represents a C2-7 alkoxycarbonyl group, a C1-6 alkylsulfonylamino group, a C6-10 arylsulfonylamino group, a C1-6 alkyl group which may have any 1 to 5 substituents selected from the later identified substituent group β or any of the following substituents (xxxiii) to (xxxvi) which may have any 1 to 3 substituents selected from the later identified substituent group α;
(xxxiii) a C6-10 aryl group, (xxxiv) a heteroaryl group, (xxxv) a C3-7 cycloalkyl group or (xxxvi) a heterocycloalkyl group,
RE, RF and RG independently represent a hydrogen atom, a cyano group, a carbamoyl group, a C2-7 acyl group, a C2-7 alkoxycarbonyl group, a C6-10 aryl(C2-7 alkoxycarbonyl group, a nitro group, a C1-6 alkylsulfonyl group, a sulfamoyl group, a carbamimidoyl group or a C1-6 alkyl group which may have any 1 to 5 substituents selected from the later identified substituent group β;
or RE and RF bind together to form an ethylene group;
or RF and RG bind together with the neighboring nitrogen atom to form an aliphatic cyclic amino group which may have a substituent selected from the later identified substituent group α;
Y represents CH or N;
Q represents —C1-6 alkylene-, —C2-6 alkenylene-, —C2-6 alkynylene-, —C1-6 alkylene-O—, —C1-6 alkylene-S—, —O—C1-6 alkylene-, —S—C1-6 alkylene-, —C1-6 alkylene-O—C1-6 alkylene-, —C1-6 alkylene-S—C1-6 alkylene-, —CON(R7)—, —N(R7)CO—, —C1-6 alkylene-CON(R7)— or —CON(R7)—C1-6 alkylene-;
R7 represents a hydrogen atom or a C1-6 alkyl group;
ring A represents a C6-10 aryl group or a heteroaryl group;
G represents a group represented by a formula:
or a formula:
E1 represents a hydrogen atom, a fluorine atom or a hydroxy group;
E2 represents a hydrogen atom, a fluorine atom, a methyl group or a hydroxymethyl group;
substituent group α:
a halogen atom, a hydroxy group, an amino group, a C1-6 alkyl group, a C1-6 alkoxy group, a halo(C1-6 alkyl) group, a halo(C1-6 alkoxy) group, a hydroxy(C1-6 alkyl) group, a C2-7 alkoxycarbonyl(C1-6 alkyl) group, a hydroxy(C1-6 alkoxy) group, an amino(C1-6 alkyl) group, an amino(C1-6 alkoxy) group, a mono or di(C1-6 alkyl)amino group, a mono or di[hydroxy(C1-6 alkyl)]amino group, a C1-6 alkylsulfonyl group, a C1-6 alkylsulfonylamino group, a C1-6 alkylsulfonylamino(C1-6 alkyl) group, a carboxy group, a C2-7 alkoxycarbonyl group, a sulfamoyl group and —CON(RH)RI
substituent group β:
a halogen atom, a hydroxy group, an amino group, a C1-6 alkoxy group, a C1-6 alkylthio group, a halo(C1-6 alkoxy) group, a halo(C1-6 alkylthio) group, a hydroxy(C1-6 alkoxy) group, a hydroxy(C1-6 group, an amino(C1-6 alkylthio) group, an amino(C1-6 alkylthio) group, a mono or di(C1-6 alkyl)amino group, a mono or di[hydroxy(C1-6 alkyl)]amino group, an ureido group, a sulfamide group, a mono or di(C1-6 alkyl)ureido group, a mono or di[hydroxy(C1-6 alkyl)]ureido group, a mono or di(C1-6 alkyl)sulfamide group, a mono or di[hydroxy(C1-6 alkyl)]-sulfamide group, a C2-7 acylamino group, an amino(C2-7 acylamino) group, a C1-6 alkylsulfonyl group, a C1-6 alkylsulfonylamino group, a carbamoyl(C1-6 alkylsulfonylamino) group, a carboxy group, a C2-7 alkoxycarbonyl group, —CON(RH)RI, and any of the following substituents (xxxvii) to (xxxxviii) which may have any 1 to 3 substituents selected from the above substituent group α on the ring;
(xxxvii) a C6-10 aryl group, (xxxviii) C6-10 aryl-O—, (xxxix) a C6-10 aryl(C1-6 alkoxy) group, (xxxx) a C6-10 aryl(C1-6 alkylthio) group, (xxxxi) a heteroaryl group, (xxxxii) heteroaryl-O—, (xxxxiii) a C3-7 cycloalkyl group, (xxxxiv) C3-7 cycloalkyl-O—, (xxxxv) a heterocycloalkyl group, (xxxxvi) heterocycloalkyl-O—, (xxxxvii) an aliphatic cyclic amino group or (xxxxviii) an aromatic cyclic amino group
RH and RI independently represent a hydrogen atom or a C1-6 alkyl group which may have any 1 to 3 substituents selected from the later identified substituent group γ;
or both of RH and RI bind together with the neighboring nitrogen atom to form an aliphatic cyclic amino group which may have any 1 to 3 substituents selected from the later identified substituent group δ;
substituent group γ:
a halogen atom, a hydroxy group, an amino group, a C1-6 alkoxy group, a halo(C1-6 alkoxy) group, a hydroxy(C1-6 alkoxy) group, an amino(C1-6 alkoxy) group, a mono or di(C1-6 alkyl)amino group, a mono or di[hydroxy(C1-6 alkyl)]amino group, an ureido group, a sulfamide group, a mono or di(C1-6 alkyl)ureido group, a mono or di[hydroxy(C1-6 alkyl)]ureido group, a mono or di(C1-6 alkyl)sulfamide group, a mono or di[hydroxy(C1-6 alkyl)]sulfamide group, a C2-7 acylamino group, an amino(C2-7 acylamino) group, a C1-6 alkylsulfonyl group, a C1-6 alkylsulfonylamino group, a carbamoyl(C1-6 alkylsulfonylamino) group, a carboxy group, a C2-7 alkoxycarbonyl group and —CON(RJ)RK
substituent group δ:
a halogen atom, a hydroxy group, an amino group, a C1-6 alkyl group, a C1-6 alkoxy group, a halo(C1-6 alkyl) group, a halo(C1-6 alkoxy) group, a hydroxy(C1-6 alkyl) group, a C2-7 alkoxycarbonyl(C1-6 alkyl) group, a hydroxy(C1-6 alkoxy) group, an amino(C1-6 alkyl) group, an amino(C1-6 alkoxy) group, a mono or di(C1-6 alkyl)amino group, a mono or di[hydroxy(C1-6 alkyl)]amino group, a C1-6 alkylsulfonyl group, a C1-6 alkylsulfonylamino group, a C1-6 alkylsulfonylamino(C1-6 alkyl) group, a carboxy group, a C2-7 alkoxycarbonyl group, a sulfamoyl group and —CON(RJ)RK
RJ and RK independently represent a hydrogen atom or a C1-6 alkyl group which may have any 1 to 3 substituents selected from a hydroxy group, an amino group, a mono or di(C1-6 alkyl)amino group, a C2-7 alkoxycarbonyl group and a carbamoyl group;
or both of RJ and RK bind together with the neighboring nitrogen atom to form an aliphatic cyclic amino group which may have any 1 to 3 substituents selected from a hydroxy group, an amino group, a mono or di(C1-6 alkyl)amino group, a C1-6 alkyl group, a hydroxy(C1-6 alkyl) group, a C2-7 alkoxycarbonyl group, a C2-7 alkoxycarbonyl(C1-6 alkyl) group and a carbamoyl group,
or a pharmaceutically acceptable salt thereof.

### Claim 21 (depends on 20)

A method for the treatment as claimed in claim 20, wherein the disease associated with hyperglycemia is a disease selected from the group consisting of diabetes, impaired glucose tolerance, diabetic complications, obesity, hyperinsulinemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, lipid metabolism disorder, atherosclerosis, hypertension, congestive heart failure, edema, hyperuricemia and gout.

### Claim 22

A method for the inhibition of advancing impaired glucose tolerance into diabetes in a subject, which comprises administering an effective amount of a nitrogen-containing fused-ring derivative represented by the following general formula (I):
wherein
R1 represents a hydrogen atom, a C1-6 alkyl group, a halo(C1-6 alkyl) group, a hydroxy(C1-6 alkyl) group, a dihydroxy(C1-6 alkyl) group, a C1-6 alkoxy(C1-6 alkyl) group, a C2-7 alkoxycarbonyl(C1-6 alkyl) group, a carboxy(C1-6 alkyl) group, a C1-6 alkenyl group, -J-N(R5)-Z1, -J-CON(R5)-Z1, or any of the following substituents (a) to (d) which may have any 1 to 3 substituents selected from the later identified substituent group α on the ring;
(a) a C3-7 cycloalkyl group, (b) a C3-7 cycloalkyl(C1-6 alkyl group, (c) a C6-10 aryl group or (d) C6-10 aryl(C1-6 alkyl group,
R2 represents a hydrogen atom, a halogen atom or a C1-6 alkyl group;
R3 and R4 independently represent a hydrogen atom, a hydroxy group, a halogen atom, a C1-6 alkyl group, a C1-6 alkenyl group, a C2-6 alkynyl group, a C1-6 alkoxy group, a C2-6 alkenyloxy group, a C1-6 alkylthio group, a C2-6 alkenylthio group, a halo(C1-6 alkyl group, a halo(C1-6 alkoxy) group, a halo(C1-6 alkylthio) group, a hydroxy(C1-6 alkyl) group, a hydroxy(C2-6 alkenyl) group, a hydroxy(C1-6 alkoxy) group, a hydroxy(C1-6 alkylthio) group, a carboxy group, a carboxy(C1-6 alkyl) group, a carboxy(C2-6 alkenyl) group, a carboxy(C1-6 alkoxy) group, a carboxy(C1-6 alkylthio) group, a C2-7 alkoxycarbonyl group, a C2-7 alkoxycarbonyl(C1-6 alkyl) group, a C2-7 alkoxycarbonyl(C2-6 alkenyl) group, a C2-7 alkoxycarbonyl(C1-6 alkoxy) group, a C2-7 alkoxycarbonyl(C1-6 alkylthio) group, a C1-6 alkylsulfinyl group, a C1-6 alkylsulfonyl group, —U—V—W—N(R6)-Z2, or any of the following substituents (i) to (xxviii) which may have any 1 to 3 substituents selected from the later identified substituent group α on the ring;
(i) a C6-10 aryl group, (ii) C6-10 aryl-O—, (iii) C6-10 aryl-S—, (iv) a C6-10 aryl(C1-6 alkyl) group, (v) a C6-10 aryl(C1-6 alkoxy) group, (vi) a C6-10 aryl(C1-6 alkylthio) group, (vii) a heteroaryl group, (viii) heteroaryl-O—, (ix) heteroaryl-S—, (x) a heteroaryl(C1-6 alkyl) group, (xi) a heteroaryl(C1-6 alkoxy) group, (xii) a heteroaryl(C1-6 alkylthio) group, (xiii) a C3-7 cycloalkyl group, (xiv) C3-7 cycloalkyl-O—, (xv) C3-7 cycloalkyl-S—, (xvi) a C3-7 cycloalkyl(C1-6 alkyl group, (xvii) a C3-7 cycloalkyl(C1-6 alkoxy) group, (xviii) a C3-7 cycloalkyl(C1-6 alkylthio) group, (xix) a heterocycloalkyl group, (xx) heterocycloalkyl-O—, (xxi) heterocycloalkyl-S—, (xxii) a heterocycloalkyl(C1-6 alkyl) group, (xxiii) a heterocycloalkyl(C1-6 alkoxy) group, (xxiv) a heterocycloalkyl(C1-6 alkylthio) group, (xxv) an aromatic cyclic amino group, (xxvi) an aromatic cyclic amino(C1-6 alkyl) group, (xxvii) an aromatic cyclic amino(C1-6 alkoxy) group, or (xxviii) an aromatic cyclic amino(C1-6 alkylthio) group,
J represents a C1-6 alkylene group which may have a hydroxy group, or a C1-6 alkenylene group;
U represents —O—, —S— or a single bond and with the proviso that at least one of V and W is not a single bond when U is —O— or —S—;
V represents a C1-6 alkylene group which may have a hydroxy group, a C2-6 alkenylene group or a single bond;
W represents —CO—, —SO2—, —C(═NH)— or a single bond;
Z1 and Z2 independently represent a hydrogen atom, a C2-7 alkoxycarbonyl group, a C6-10 aryl(C2-7 alkoxycarbonyl) group, a formyl group, —RA, —CORB, —SO2RB, —CON(RC)RD, —CSN(RC)RD, —SO2NHRA or —C(═NRE)N(RF)RG;
R5, R6, RA, RC and RD independently represent a hydrogen atom, a C1-6 alkyl group which may have any 1 to 5 substituents selected from the later identified substituent group, or any of the following substituents (xxix) to (xxxii) which may have any 1 to 3 substituents selected from the later identified substituent group α;
(xxix) a C6-10 aryl group, (xxx) a heteroaryl group, (xxxi) a C3-7 cycloalkyl group or (xxxii) a heterocycloalkyl group,
or both of Z1 and R5 or both of Z2 and R6 bind together with the neighboring nitrogen atom to form an aliphatic cyclic amino group which may have any 1 to 3 substituents selected from the later identified substituent group α;
or RC and RD bind together with the neighboring nitrogen atom to form an aliphatic cyclic amino group which may have any 1 to 3 substituents selected from the later identified substituent group α;
RB represents a C2-7 alkoxycarbonyl group, a C1-6 alkylsulfonylamino group, a C6-10 arylsulfonylamino group, a C1-6 alkyl group which may have any 1 to 5 substituents selected from the later identified substituent group P or any of the following substituents (xxxiii) to (xxxvi) which may have any 1 to 3 substituents selected from the later identified substituent group α;
(xxxiii) a C6-10 aryl group, (xxxiv) a heteroaryl group, (xxxv) a C3-7 cycloalkyl group or (xxxvi) a heterocycloalkyl group,
RE, RF and RG independently represent a hydrogen atom, a cyano group, a carbamoyl group, a C2-7 acyl group, a C2-7 alkoxycarbonyl group, a C6-10 aryl(C2-7 alkoxycarbonyl) group, a nitro group, a C1-6 alkylsulfonyl group, a sulfamoyl group, a carbamimidoyl group or a C1-6 alkyl group which may have any 1 to 5 substituents selected from the later identified substituent group β;
or RE and RF bind together to form an ethylene group;
or RF and RG bind together with the neighboring nitrogen atom to form an aliphatic cyclic amino group which may have a substituent selected from the later identified substituent group α;
Y represents CH or N;
Q represents —C1-6 alkylene-, —C2-6 alkenylene-, —C2-6 alkynylene-, —C1-6 alkylene-O—, —C1-6 alkylene-S—, —O—C1-6 alkylene-, —S—C1-6 alkylene-, —C1-6 alkylene-O—C1-6 alkylene-, —C1-6 alkylene-S—C1-6 alkylene-, —CON(R7)—, —N(R7)CO—, —C1-6 alkylene-CON(R7)— or —CON(R7)—C1-6 alkylene-;
R7 represents a hydrogen atom or a C1-6 alkyl group;
ring A represents a C6-10 aryl group or a heteroaryl group;
G represents a group represented by a formula:
or a formula:
E1 represents a hydrogen atom, a fluorine atom or a hydroxy group;
E2 represents a hydrogen atom, a fluorine atom, a methyl group or a hydroxymethyl group;
substituent group α:
a halogen atom, a hydroxy group, an amino group, a C1-6 alkyl group, a C1-6 alkoxy group, a halo(C1-6 alkyl) group, a halo(C1-6 alkoxy) group, a hydroxy(C1-6 alkyl) group, a C2-7 alkoxycarbonyl(C1-6 alkyl) group, a hydroxy(C1-6 alkoxy) group, an amino(C1-6 alkyl) group, an amino(C1-6 alkoxy) group, a mono or di(C1-6 alkyl)amino group, a mono or di[hydroxy(C1-6 alkyl)]amino group, a C1-6 alkylsulfonyl group, a C1-6 alkylsulfonylamino group, a C1-6 alkylsulfonylamino(C1-6 alkyl) group, a carboxy group, a C2-7 alkoxycarbonyl group, a sulfamoyl group and —CON(RH)RI
substituent group β;
a halogen atom, a hydroxy group, an amino group, a C1-6 alkoxy group, a C1-6 alkylthio group, a halo(C1-6 alkoxy) group, a halo(C1-6 alkylthio) group, a hydroxy(C1-6 alkoxy) group, a hydroxy(C1-6 alkylthio) group, an amino(C1-6 alkoxy group, an amino(C1-6 alkylthio) group, a mono or di(C1-6 alkyl)amino group, a mono or di[hydroxy(C1-6 alkyl)]amino group, an ureido group, a sulfamide group, a mono or di(C1-6 alkyl)ureido group, a mono or di[hydroxy(C1-6 alkyl)]ureido group, a mono or di(C1-6 alkyl)sulfamide group, a mono or di[hydroxy(C1-6 alkyl]-sulfamide group, a C2-7 acylamino group, an amino(C2-7 acylamino) group, a C1-6 alkylsulfonyl group, a C1-6 alkylsulfonylamino group, a carbamoyl(C1-6 alkylsulfonylamino) group, a carboxy group, a C2-7 alkoxycarbonyl group, —CON(RH)RI, and any of the following substituents (xxxvii) to (xxxxviii) which may have any 1 to 3 substituents selected from the above substituent group α on the ring;
(xxxvii) a C6-10-aryl group, (xxxviii) C6-10 aryl-O—, (xxxix) a C6-10 aryl(C1-6 alkoxy) group, (xxxx) a C6-10 aryl(C1-6 alkylthio) group, (xxxxi) a heteroaryl group, (xxxxii) heteroaryl-O—, (xxxxiii) a C3-7 cycloalkyl group, (xxxxiv) C3-7 cycloalkyl-O—, (xxxxv) a heterocycloalkyl group, (xxxxvi) heterocycloalkyl-O—, (xxxxvii) an aliphatic cyclic amino group or (xxxxviii) an aromatic cyclic amino group
RH and RI independently represent a hydrogen atom or a C1-6 alkyl group which may have any 1 to 3 substituents selected from the later identified substituent group γ;
or both of RH and RI bind together with the neighboring nitrogen atom to form an aliphatic cyclic amino group which may have any 1 to 3 substituents selected from the later identified substituent group δ;
substituent group γ:
a halogen atom, a hydroxy group, an amino group, a C1-6 alkoxy group, a halo(C1-6 alkoxy) group, a hydroxy(C1-6 alkoxy) group, an amino(C1-6 alkoxy) group, a mono or di(C1-6 alkyl)amino group, a mono or di[hydroxy(C1-6 alkyl]amino group, an ureido group, a sulfamide group, a mono or di(C1-6 alkyl)ureido group, a mono or di[hydroxy(C1-6 alkyl)]ureido group, a mono or di(C1-6 alkyl)sulfamide group, a mono or di[hydroxy(C1-6 alkyl)]sulfamide group, a C2-7 acylamino group, an amino(C2-7 acylamino) group, a C1-6 alkylsulfonyl group, a C1-6 alkylsulfonylamino group, a carbamoyl(C1-6 alkylsulfonylamino) group, a carboxy group, a C2-7 alkoxycarbonyl group and —CON(RJ)RK
substituent group δ:
a halogen atom, a hydroxy group, an amino group, a C1-6 alkyl group, a C1-6 alkoxy group, a halo(C1-6 alkyl) group, a halo(C1-6 alkoxy) group, a hydroxy(C1-6 alkyl) group, a C2-7 alkoxycarbonyl(C1-6 alkyl) group, a hydroxy(C1-6 alkoxy) group, an amino(C1-6 alkyl) group, an amino(C1-6 alkoxy) group, a mono or di(C1-6 alkyl)amino group, a mono or di[hydroxy(C1-6 alkyl)]amino group, a C1-6 alkylsulfonyl group, a C1-6 alkylsulfonylamino group, a C1-6 alkylsulfonylamino(C1-6 alkyl) group, a carboxy group, a C2-7 alkoxycarbonyl group, a sulfamoyl group and —CON(RJ)RK
RJ and RK independently represent a hydrogen atom or a C1-6 alkyl group which may have any 1 to 3 substituents selected from a hydroxy group, an amino group, a mono or di(C1-6 alkyl)amino group, a C2-7 alkoxycarbonyl group and a carbamoyl group;
or both of RJ and RK bind together with the neighboring nitrogen atom to form an aliphatic cyclic amino group which may have any 1 to 3 substituents selected from a hydroxy group, an amino group, a mono or di(C1-6 alkyl) amino group, a C1-6 alkyl group, a hydroxy(C1-6 alkyl) group, a C2-7 alkoxycarbonyl group, a C2-7 alkoxycarbonyl(C1-6 alkyl) group and a carbamoyl group,
or a pharmaceutically acceptable salt thereof.

### Claim at position 6

-26. (canceled)

### Claim 27

A pharmaceutical composition comprising as an active ingredient a therapeutically effective amount of a nitrogen-containing fused-ring derivative represented by the following general formula (I):
wherein
R1 represents a hydrogen atom, a C1-6 alkyl group, a halo(C1-6 alkyl) group, a hydroxy(C1-6 alkyl) group, a dihydroxy(C1-6 alkyl) group, a C1-6 alkoxy(C1-6 alkyl) group, a C2-7 alkoxycarbonyl(C1-6 alkyl) group, a carboxy(C1-6 alkyl) group, a C2-6 alkenyl group, -J-N(R5)-Z1, -J-CON(R5)-Z1, or any of the following substituents (a) to (d) which may have any 1 to 3 substituents selected from the later identified substituent group α on the ring;
(a) a C3-7 cycloalkyl group, (b) a C3-7 cycloalkyl(C1-6 alkyl) group, (c) a C6-10 aryl group or (d) a C6-10 aryl(C1-6 alkyl) group,
R2 represents a hydrogen atom, a halogen atom or a C1-6 alkyl group;
R3 and R4 independently represent a hydrogen atom, a hydroxy group, a halogen atom, a C1-6 alkyl sroup, a C1-6 alkenyl group, a C1-6 alkynyl group, a C1-6 alkoxy group, a C2-6 alkenyloxy group, a C1-6 alkylthio group, a C2-6 alkenylthio group, a halo(C1-6 alkyl) group, a halo(C1-6 alkoxy) group, a halo(C1-6 alkylthio) group, a hydroxy(C1-6 alkyl) group, a hydroxy(C2-6 alkenyl) group, a hydroxy(C1-6 alkoxy) group, a hydroxy(C1-6 alkylthio) group, a carboxy group, a carboxy(C1-6 alkyl) group, a carboxy(C1-6 alkenyl) group, a carboxy(C1-6 alkoxy) group, a carboxy(C1-6 alkylthio) group, a C2-7 alkoxycarbonyl group, a C2-7 alkoxycarbonyl(C1-6 alkyl) group, a C2-7 alkoxycarbonyl(C2-6 alkoxy) group, a C2-7 alkoxycarbonyl(C1-6 alkoxy) group, a C2-7 alkoxycarbonyl(C1-6 alkylthio) group, a C1-6 alkylsulfinyl group, a C1-6 alkylsulfonyl group, —U—V—W—N(R6)-Z2, or any of the following substituents (i) to (xxviii) which may have any 1 to 3 substituents selected from the later identified substituent group α on the ring;
(i) a C6-10 aryl group, (ii) C6-10 aryl-O—, (C6-10 alkyl) group, (v) a —C6-10 aryl(C1-6 alkoxy) group, (vi) a C6-10 aryl(C1-6 alkylthio) group, (vii) a heteroaryl group, (viii) heteroaryl-O—, (ix) heteroaryl-S—, (x) a heteroaryl(C1-6 alkyl) group, (xi) a heteroaryl(C1-6 alkoxy) group, (xii) a heteroaryl(C1-6 alkylthio) group, (xiii) a C3-7 cycloalkyl group, (xiv) C3-7 cycloalkyl-O—, (xv) C3-7 cycloalkyl-S—, (xvi) a C3-7 cycloalkyl(C1-6 alkyl) group (xvii) a C3-7 cycloalkyl(C1-6 alkylthio) group (xix) a heterocycloalkyl group, (xx) heterocycloalkyl-O—, (xxi) heterocycloalkyl-S—, (xxii) a heterocycloalkyl(C1-6 alkyl) group, (xxiii) a heterocycloalkyl(C1-6 alkoxy) group, (xxiv) a heterocycloalkyl(C1-6 alkylthio) group, (xxv) an aromatic cyclic amino group, (xxvi) an aromatic cyclic amino(C1-6 alkyl) group, (xxvii) an aromatic cyclic amino(C1-6 alkoxy) group, or (xxviii) an aromatic cyclic amino(C1-6 alkylthio) group,
J represents a C1-6 alkylene group which may have a hydroxy group, or a C2-6 alkenylene group;
U represents —O—, —S— or a single bond and with the proviso that at least one of V and W is not a single bond when U is —O— or —S—;
V represents a C1-6 alkylene group which may have a hydroxy group, a C2-6 alkenylene group or a single bond;
W represents —CO—, —SO_—, —C(═NH)— or a single bond;
Z1 and Z2 independently represent a hydrogen atom, a C2-7 alkoxycarbonyl group, a C6-10 aryl(C2-7 alkoxycarbonyl) group, a formyl group, —RA, —CORB, —SO2RB, —CON(RC)RD, —CSN(RC)RD, —SO2NHRA or —C(═NRE)N(RF)RG;
R5, R6, RA, RC and RD independently represent a hydrogen atom, a C1-6 alkyl group which may have any 1 to 5 substituents selected from the later identified substituent group β or any of the following substituents (xxix) to (xxxii) which may have any 1 to 3 substituents selected from the later identified substituent group α;
(xxix) a C6-10 aryl group, (xxx) a heteroaryl group, (xxxi) a C3-7 cycloalkyl group or (xxxii) a heterocycloalkyl group,
or both of Z1 and R5 or both of Z2 and R6 bind together with the neighboring nitrogen atom to form an aliphatic cyclic amino group which may have any 1 to 3 substituents selected from the later identified substituent group α;
or RC and RD bind together with the neighboring nitrogen atom to form an aliphatic cyclic amino group which may have any 1 to 3 substituents selected from the later identified substituent group α;
RB represents a C2-7 alkoxycarbonyl group, a C1-6 alkylsulfonylamino group, a C6-10 arylsulfonylamino group, a C1-6 alkyl group which may have any 1 to 5 substituents selected from the later identified substituent group β or any of the following substituents (xxxiii) to (xxxvi) which may have any 1 to 3 substituents selected from the later identified substituent group α;
(xxxiii) a C6-10 aryl group (xxxiv) a heteroaryl group, (xxxv) a C3-7 cycloalkyl group or (xxxvi) a heterocycloalkyl group,
RE, RF and RG independently represent a hydrogen atom, a cyano group, a carbamoyl group, a C2-7 acyl group, a C2-7 alkoxycarbonyl group, a C6-10 aryl(C2-7 alkoxycarbonyl) group, a nitro group, a C1-6 alkylsulfonyl group, a sulfamoyl group, a carbamimidoyl group or a C1-6 alkyl group which may have any 1 to 5 substituents selected from the later identified substituent group β;
or RE and RF bind together to form an ethylene group;
or RF and RG bind together with the neighboring nitrogen atom to form an aliphatic cyclic amino group which may have a substituent selected from the later identified substituent group α;
Y represents CH or N;
Q represents —C1-6 alkylene-, —C2-6 alkenylene-, —C2-6 alkynylene-, —C1-6 alkylene-O—, —C1-6 alkylene-S—, —O—C1-6 alkylene-, —S—C1-6 alkylene-, —C1-6 alkylene-O—C1-6 alkylene-, —C1-6 alkylene-S—C1-6 alkylene-, —CON(R7)—, —N(R7)CO—, —C1-6 alkylene-CON(R7)— or —CON(R7)—C1-6 alkylene-;
R7 represents a hydrogen atom or a C1-6 alkyl group;
ring A represents a C6-10 aryl group or a heteroaryl group;
G represents a group represented by a formula:
or a formula:
E1 represents a hydrogen atom, a fluorine atom or a hydroxy group;
E2 represents a hydrogen atom, a fluorine atom, a methyl group or a hydroxymethyl group;
substituent group α:
a halogen atom, a hydroxy group, an amino group, a C1-6 alkyl group, a C1-6 alkoxy group, a halo(C1-6 alkyl) group, a halo(C1-6 alkoxy) group, a hydroxy(C1-6 alkyl) group, a C2-7 alkoxycarbonyl(C1-6 alkyl) group, a hydroxy(C1-6 alkoxy) group, an amino(C1-6 alkyl) group, an amino(C1-6 alkoxy) group, a mono or di(C1-6 alkyl)amino group, a mono or di[hydroxy(C1-6 alkyl)]amino group, a C1-6 alkylsulfonyl group, a C1-6 alkylsulfonylamino group, a C1-6 alkylsulfonylamino(C1-6 alkyl) group, a carboxy group, a C2-7 alkoxycarbonyl group, a sulfamoyl group and —CON(RH)RI
substituent group β:
a halogen atom, a hydroxy group, an amino group, a C1-6 alkoxy group, a C1-6 alkylthio group, a halo(C1-6 alkoxy) group, a halo(C1-6 alkylthio) group, a hydroxy(C1-6 alkoxy) group, a hydroxy(C1-6 alkylthio) group, an amino(C1-6 alkoxy) group, an amino(C1-6 alkylthio) group, a mono or di(C1-6 alkyl)amino group, a mono or di[hydroxy(C1-6 alkyl)]amino group, an ureido group, a sulfamide group, a mono or di(C1-6 alkyl)ureido group, a mono or di[hydroxy(C1-6 alkyl)]ureido group, a mono or di(C1-6 alkyl)sulfamide group, a mono or di[hydroxy(C1-6 alkyl)]sulfamide group, a C2-7 acylamino group, an amino(C2-7 acylamino) group, a C1-6 alkylsulfonyl group, a C1-6 alkylsulfonylamino group, a carbamoyl(C1-6 alkylsulfonylamino) group, a carboxy group, a C2-7 alkoxycarbonyl group, —CON(RH)RI, and any of the following substituents (xxxvii) to (xxxxviii) which may have any 1 to 3 substituents selected from the above substituent group α on the ring;
(xxxvii) a C6-10 aryl group, (xxxviii) C6-10 aryl-O—, (xxxix) a C6-10 aryl(C1-6 alkoxy) group (xxxx) a C6-10 aryl(C1-6 alkylthio) group, (xxxxi) a heteroaryl group, (xxxxii) heteroaryl-O—, (xxxxiii) a C3-7 cycloalkyl group, (xxxxiv) C3-7 cycloalkyl-O—, (xxxxv) a heterocycloalkyl group, (xxxxvi) heterocycloalkyl-O—, (xxxxvii) an aliphatic cyclic amino group or (xxxxviii) an aromatic cyclic amino group
RH and RI independently represent a hydrogen atom or a C1-6 alkyl group which may have any 1 to 3 substituents selected from the later identified substituent group γ;
or both of RH and RI bind together with the neighboring nitrogen atom to form an aliphatic cyclic amino group which may have any 1 to 3 substituents selected from the later identified substituent group δ;
substituent group γ:
a halogen atom, a hydroxy group, an amino group, a C1-6 alkoxy group, a halo(C1-6 alkoxy) group, a hydroxy(C1-6 alkoxy group, an amino(C1-6 alkoxy) group, a mono or di(C1-6 alkyl)amino group, a mono or di[hydroxy(C1-6 alkyl)]amino group, an ureido group, a sulfamide group, a mono or di(C1-6 alkyl)ureido group, a mono or di[hydroxy(C1-6 alkyl)]ureido group, a mono or di(C1-6 alkyl)sulfamide group, a mono or di[hydroxy(C1-6 alkyl)]sulfamide group, a C2-7 acylamino group, an amino(C2-7 acylamino) group, a C1-6 alkylsulfonyl group, a C1-6 alkylsulfonylamino group, a carbamoyl(C1-6 alkylsulfonylamino) group, a carboxy group, a C2-7 alkoxycarbonyl group and —CON(RJ)RK
substituent group δ:
a halogen atom, a hydroxy group, an amino group, a C1-6 alkyl group, a C1-6 alkoxy group, a halo(C1-6 alkyl) group, a halo(C1-6 alkoxy) group, a hydroxy(C1-6 alkyl) group, a C2-7 alkoxycarbonyl(C1-6 alkyl) group, a hydroxy(C1-6 alkoxy) group, an amino(C1-6 alkyl) group, an amino(C1-6 alkoxy) group, a mono or di(C1-6 alkyl)amino group, a mono or di[hydroxy(C1-6 alkyl)]amino group, a C1-6 alkylsulfonyl group, a C1-6 alkylsulfonylamino group, a C1-6 alkylsulfonylamino(C1-6 alkyl) group, a carboxy group, a C2-7 alkoxycarbonyl group, a sulfamoyl group and —CON(RJ)RK
RJ and RK independently represent a hydrogen atom or a C1-6 alkyl group which may have any 1 to 3 substituents selected from a hydroxy group, an amino group, a mono or di(C1-6 alkyl)amino group, a C2-7 alkoxycarbonyl group and a carbamoyl group;
or both of RJ and RK bind together with the neighboring nitrogen atom to form an aliphatic cyclic amino group which may have any 1 to 3 substituents selected from a hydroxy group, an amino groups a mono or di(C1-6 alkyl)amino group, a C1-6 alkyl group, a hydroxy(C1-6 alkyl) group, a C2-7 alkoxycarbonyl group, a C2-7 alkoxycarbonyl(C1-6 alkyl) group and a carbamoyl group,
or a pharmaceutically acceptable salt thereof.
which is in combination with at least one member selected from the group consisting of an insulin sensitivity enhancer, a glucose absorption inhibitor, a biguanide, an insulin secretion enhancer, a SGLT2 inhibitor, an insulin or insulin analogue, a glucagon receptor antagonist, an insulin receptor kinase stimulant, a tripeptidyl peptidase II inhibitor, a dipeptidyl peptidase IV inhibitor, a protein tyrosine phosphatase-1B inhibitor, a glycogen phosphorylase inhibitor, a glucose-6-phosphatase inhibitor, a fructose-bisphosphatase inhibitor, a pyruvate dehydrogenase inhibitor, a hepatic gluconeogenesis inhibitor, D-chiroinsitol, a glycogen synthase kinase-3 inhibitor, glucagon-like peptide-1, a glucagon-like peptide-1 analogue, a glucagon-like peptide-1 agonist, amylin, an amylin analogue, an amylin agonist, an aldose reductase inhibitor, an advanced glycation endproducts formation inhibitor, a protein kinase C inhibitor, a γ-aminobutyric acid receptor antagonist, a sodium channel antagonist, a transcript factor NF-κB inhibitor, a lipid peroxidase inhibitor, an N-acetylated-α-linked-acid-dipeptidase inhibitor, insulin-like growth factor-I, platelet-derived growth factor, a platelet-derived growth factor analogue, epidermal growth factor, nerve growth factor, a carnitine derivative, uridine, 5-hydroxy-1-methylhydantoin, EGB-761, bimoclomol, sulodexide, Y-128, antidiarrhoics, cathartics, a hydroxymethylglutaryl coenzyme A reductase inhibitor, a fibrate, a β3-adrenoceptor agonist, an acyl-coenzyme A cholesterol acyltransferase inhibitor, probcol, a thyroid hormone receptor agonist, a cholesterol absorption inhibitor, a lipase inhibitor, a microsomal triglyceride transfer protein inhibitor, a lipoxygenase inhibitor, a carnitine palmitoyl-transferase inhibitor, a squalene synthase inhibitor, a low-density lipoprotein receptor enhancer, a nicotinic acid derivative, a bile acid sequestrant, a sodium/bile acid cotransporter, inhibitor, a cholesterol ester transfer protein inhibitor, an appetite suppressant, an angiotensin-converting enzyme inhibitor, a neutral endopeptidase inhibitor, an angiotensin II receptor antagonist, an endothelin-converting enzyme inhibitor, an endothelin receptor antagonist, a diuretic agent, a calcium antagonist, a vasodilating antihypertensive agent, a sympathetic blocking agent, a centrally acting antihypertensive agent, an α2-adrenoceptor agonist, an antiplatelets agent, a uric acid synthesis inhibitor, a uricosuric agent and a urinary alkalinizer.

### Claim 28

(canceled)

### Claim 29 (depends on 19)

A method for the inhibition of postprandial hyperglycemia as claimed in claim 19, which comprises administering in combination with at least one member selected from the group consisting of an insulin sensitivity enhancer, a glucose absorption inhibitor, a biguanide, an insulin secretion enhancer, a SGLT2 inhibitor, an insulin or insulin analogue, a glucagon receptor antagonist, an insulin receptor kinase stimulant, a tripeptidyl peptidase II inhibitor, a dipeptidyl peptidase IV inhibitor, a protein tyrosine phosphatase-1B inhibitor, a glycogen phosphorylase inhibitor, a glucose-6-phosphatase inhibitor, a fructose-bisphosphatase inhibitor, a pyruvate dehydrogenase inhibitor, a hepatic gluconeogenesis inhibitor, D-chiroinsitol, a glycogen synthase kinase-3 inhibitor, glucagon-like peptide-1, a glucagon-like peptide-1 analogue, a glucagon-like peptide-1 agonist, amylin, an amylin analogue, an amylin agonist, an aldose reductase inhibitor, an advanced glycation endproducts formation inhibitor, a protein kinase C inhibitor, a γ-aminobutyric acid receptor antagonist, a sodium channel antagonist, a transcript factor NF-κB inhibitor, a lipid peroxidase inhibitor, an N-acetylated-α-linked-acid-dipeptidase inhibitor, insulin-like growth factor-I, platelet-derived growth factor, a platelet-derived growth factor analogue, epidermal growth factor, nerve growth factor, a carnitine derivative, uridine, 5-hydroxy-1-methylhydantoin, EGB-761, bimoclomol, sulodexide, Y-128, antidiarrhoics, cathartics, a hydroxymethylglutaryl coenzyme A reductase inhibitor, a fibrate, a β3-adrenoceptor agonist, an acyl-coenzyme A cholesterol acyltransferase inhibitor, probcol, a thyroid hormone receptor agonist, a cholesterol absorption inhibitor, a lipase inhibitor, a microsomal triglyceride transfer protein inhibitor, a lipoxygenase inhibitor, a carnitine palmitoyl-transferase inhibitor, a squalene synthase inhibitor, a low-density lipoprotein receptor enhancer, a nicotinic acid derivative, a bile acid sequestrant, a sodium/bile acid cotransporter inhibitor, a cholesterol ester transfer protein inhibitor, an appetite suppressant, an angiotensin-converting enzyme inhibitor, a neutral endopeptidase inhibitor, an angiotensin II receptor antagonist, an endothelin-converting enzyme inhibitor, an endothelin receptor antagonist, a diuretic agent, a calcium antagonist, a vasodilating antihypertensive agent, a sympathetic blocking agent, a centrally acting antihypertensive agent, an α2-adrenoceptor agonist, an antiplatelets agent, a uric acid synthesis inhibitor, a uricosuric agent and a urinary alkalinizer.

### Claim 30 (depends on 20)

A method for the prevention or treatment of a disease associated with hyperglycemia as claimed in claim 20, which comprises administering in combination with at least one member selected from the group consisting of an insulin sensitivity enhancer, a glucose absorption inhibitor, a biguanide, an insulin secretion enhancer, a SGLT2 inhibitor, an insulin or insulin analogue, a glucagon receptor antagonist, an insulin receptor kinase stimulant, a tripeptidyl peptidase II inhibitor, a dipeptidyl peptidase IV inhibitor, a protein tyrosine phosphatase-1B inhibitor, a glycogen phosphorylase inhibitor, a glucose-6-phosphatase inhibitor, a fructose-bisphosphatase inhibitor, a pyruvate dehydrogenase inhibitor, a hepatic gluconeogenesis inhibitor, D-chiroinsitol, a glycogen synthase kinase-3 inhibitor, glucagon-like peptide-1, a glucagon-like peptide-I analogue, a glucagon-like peptide-1 agonist, amylin, an amylin analogue, an amylin agonist, an aldose reductase inhibitor, an advanced glycation endproducts formation inhibitor, a protein kinase C inhibitor, a γ-aminobutyric acid receptor antagonist, a sodium channel antagonist, a transcript factor NF-κB inhibitor, a lipid peroxidase inhibitor, an N-acetylated-α-linked-acid-dipeptidase inhibitor, insulin-like growth factor-I, platelet-derived growth factor, a platelet-derived growth factor analogue, epidermal growth factor, nerve growth factor, a carnitine derivative, uridine, 5-hydroxy-1-methylhydantoin, EGB-761, bimoclomol, sulodexide, Y-128, antidiarrhoics, cathartics, a hydroxymethylglutaryl coenzyme A reductase inhibitor, a fibrate, a β3-adrenoceptor agonist, an acyl-coenzyme A cholesterol acyltransferase inhibitor, probcol, a thyroid hormone receptor agonist, a cholesterol absorption inhibitor, a lipase inhibitor, a microsomal triglyceride transfer protein inhibitor, a lipoxygenase inhibitor, a carnitine palmitoyl-transferase inhibitor, a squalene synthase inhibitor, a low-density lipoprotein receptor enhancer, a nicotinic acid derivative, a bile acid sequestrant, a sodium/bile acid cotransporter inhibitor, a cholesterol ester transfer protein inhibitor, an appetite suppressant, an angiotensin-converting enzyme inhibitor, a neutral endopeptidase inhibitor, an angiotensin II receptor antagonist, an endothelin-converting enzyme inhibitor, an endothelin receptor antagonist, a diuretic agent, a calcium antagonist, a vasodilating antihypertensive agent, a sympathetic blocking agent, a centrally acting antihypertensive agent, an α2-adrenoceptor agonist, an antiplatelets agent, a uric acid synthesis inhibitor, a uricosuric agent and a urinary alkalinizer.

### Claim 31 (depends on 22)

A method for the inhibition of advancing impaired glucose tolerance into diabetes in a subject as claimed in claim 22, which comprises administering in combination with at least one member selected from the group consisting of an insulin sensitivity enhancer, a glucose absorption inhibitor, a biguanide, an insulin secretion enhancer, a SGLT2 inhibitor, an insulin or insulin analogue, a glucagon receptor antagonist, an insulin receptor kinase stimulant, a tripeptidyl peptidase II inhibitor, a dipeptidyl peptidase IV inhibitor, a protein tyrosine phosphatase-1B inhibitor, a glycogen phosphorylase inhibitor, a glucose-6-phosphatase inhibitor, a fructose-bisphosphatase inhibitor, a pyruvate dehydrogenase inhibitor, a hepatic gluconeogenesis inhibitor, D-chiroinsitol, a glycogen synthase kinase-3 inhibitor, glucagon-like peptide-1, a glucagon-like peptide-1 analogue, a glucagon-like peptide-1 agonist, amylin, an amylin analogue, an amylin agonist, an aldose reductase inhibitor, an advanced glycation endproducts formation inhibitor, a protein kinase C inhibitor, a γ-aminobutyric acid receptor antagonist, a sodium channel antagonist, a transcript factor NF-κB inhibitor, a lipid peroxidase inhibitor, an N-acetylated-α-linked-acid-dipeptidase inhibitor, insulin-like growth factor-I, platelet-derived growth factor, a platelet-derived growth factor analogue, epidermal growth factor, nerve growth factor, a carnitine derivative, uridine, 5-hydroxy-1-methylhydantoin, EGB-761, bimoclomol, sulodexide, Y-128, antidiarrhoics, cathartics, a hydroxymethylglutaryl coenzyme A reductase inhibitor, a fibrate, a β3-adrenoceptor agonist, an acyl-coenzyme A cholesterol acyltransferase inhibitor, probcol, a thyroid hormone receptor agonist, a cholesterol absorption inhibitor, a lipase inhibitor, a microsomal triglyceride transfer protein inhibitor, a lipoxygenase inhibitor, a carnitine palmitoyl-transferase inhibitor, a squalene synthase inhibitor, a low-density lipoprotein receptor enhancer, a nicotinic acid derivative, a bile acid sequestrant, a sodium/bile acid cotransporter inhibitor, a cholesterol ester transfer protein inhibitor, an appetite suppressant, an angiotensin-converting enzyme inhibitor, a neutral endopeptidase inhibitor, an angiotensin II receptor antagonist, an endothelin-converting enzyme inhibitor, an endothelin receptor antagonist, a diuretic agent, a calcium antagonist, a vasodilating antihypertensive agent, a sympathetic blocking agent, a centrally acting antihypertensive agent, an α2-adrenoceptor agonist, an antiplatelets agent, a uric acid synthesis inhibitor, a uricosuric agent and a urinary alkalinizer.

### Claim at position 12

-34. (canceled)

### Claim 35 (depends on 30)

A method as claimed in claim 30, wherein the disease associated with hyperglycemia is the disease selected from the group consisting of diabetes, impaired glucose tolerance, diabetic complications, obesity, hyperinsulinemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, lipid metabolism disorder, atherosclerosis, hypertension, congestive heart failure, edema, hyperuricemia and gout.
